NASDAQ: AVCO

www.avalon-globocare.com

March 2020

Corporate Presentation

Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current

expectations of future events based on certain assumptions and include any statement that does not directly relate to any

historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as

a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at

their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may

differ materially because of more general factors including (without limitation) general industry and market conditions

and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements

included in this presentation represent the Company's views as of the date of this presentation and these views could

change. However, while the Company may elect to update these forward-looking statements at some point in the future,

the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon

as representing the Company's views as of any date subsequent to the date of this presentation.

2

Forward-Looking Statements

3

Corporate Overview

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, leading bio-developer of innovative

and transformative cell-based technology and therapeutics

• History: Founded in 2016; Headquarters in Freehold, NJ

• Core

Technology

Platforms:

• Strong proprietary technologies and IPs: addressing multi-billion dollar, unmet gene andcell therapy markets worldwide

• Seamless integration of verticals: fostering and accelerating translational research,clinical development and product commercialization

Immune Effector Cell Therapy

Exosome-Based Regenerative Technology (ACTEX ) “Avalon Clinical-grade, Tissue-specific Exosomes”

TM

Chimeric Antigen Receptor (CAR)-T: AVA-001, AVA-101, AVA-102

4

Investment Highlights

• Successfully uplisted from OTCQB to NASDAQ in December 2018

• Purchased headquarters building in Freehold/New Jersey in 2016 (USD $8M), which generates average annual revenue of USD $1.2M

Worldwide Headquarters:Avalon Executive CenterFreehold, New Jersey, USA

USA: Freehold, NJTampa, FLSeattle, WA

China: BeijingShanghaiNanjing

5

Investment Highlights

• Successfully filed for USD $50M mixed shelf offering (S3)

in January 2019; subsequently completed USD $6M

registered direct offering with institutional investors led

by Roth Capital Partners

• Joined Russell 3000 Index in June 2019

• Chairman provided USD $20M credit facility;

repurchased 100% of 1.7 million outstanding warrants,

enabling acceleration of R&D

“With unique infrastructure and research programs, Avalon is positioned for colossal growth ahead, with financials and valuation indicate highly asymmetric rewards to risks profile”

“Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters….”

Seeking Alpha (June 25, 2019)

Senior Management

* with contractual collaboration

Senior Management / BOD / SCAB

Scientific & ClinicalAdvisory

Board

Board of Directors

6

7

Subsidiaries/JV structure adds flexibility and focus

Avalon Subsidiaries & Joint Ventures

Differentiating Features and Uniqueness

Seamless integration of verticals to accelerate

research, clinical study, product development and commercialization

Upstream: innovative research, novel diagnostic and therapeutic targets

Midstream: bioprocessing, bioproduction, standardization, QC/QA

Downstream: clinical programs, medical team and facility, product commercialization

8

Major Clinical Bases and TR Facilities

China (Nanjing) Cell Valley

• Beijing Lu Daopei Hospital• Hebei Yanda Lu Daopei Hospital• Shanghai Lu Daopei Hospital• Lu Daopei Medical Group• Wuhan Biolake Stem Cell Bank• Lu Daopei Hematology Research Institute• Performed 1081 cases of HSCT in 2019• Performed 750 cases of CAR-T in 2019• Top-ranked hematology and BMT program in China

9

10

Expansion

Re-engineeringT cellsIsolation

Re-infusion

CAR-T Cell

CancerCell

Core Technology Platform 1:

Immune Effector Cell Therapy

Global Immuno-oncology Therapy Market

Cancer Immunotherapies by Technology TypeCAGR 14.6% 2017-2022

Source: Zion Market Research

11

12

QTY Protein/Ab Design

AVA-001

AVA-101

AVA-102

Expansion Activators

Avalon’s Cellular Medicine Pipeline Candidates:

Targeting Broad Bandwidth of Immuno-Oncology

MultiplexCAR*

*CAR: Chimeric Antigen Receptor

Cytokine / Chemokine“Trap”

MacrophageDendritic Cell

4-1BB CAR-T

Transposon CAR-T

RNA CAR-T

Core Technology Platform 1:

Immune Effector Cell Therapy

ClinicalTrials.gov Identifier: NCT03952923

AVA-001 (Second-Gen CAR-T)

13

Avalon’s next-generation transposon-based CAR-T technology:

• Multiple targets (increased efficacy)

• Applicable in multiple cell types: CAR-T, CAR-NK,

universal CAR-T/-NK

• Transposon-engineered, non-viral vector

(expanded package)

• “Safety-switch” control mechanism; reduced

cytokine release syndrome & neurotoxicity

• Shorter bio-manufacturing time

• Strong intellectual propertiesPR on January 26, 2019

AVA-101 (Next-Gen CAR-T)

14

15

Avalon’s Clinical Study Pipeline:

Immune Effector Cell Therapy Candidates

Program Pre-clinicalDesign control /

IND enabling Regulatory PathwayClinical Development

Safety Efficacy Pivotal

AVA-101(CD19xCD22 CAR-T)

US FDA & China FDA Initiation by

2020 Q3B-ALL, NHL Initiation by

2019 Q3

AVA-001(CD19 CAR-T)

China FDA Initiation by

2019 Q4B-ALL, NHL

AVA-102(CDH17 CAR-T)

US FDA & China FDA Initiation by 2020 Q4

Gastric / Colorectal CA Initiation by 2020 Q2

16

Avalon-MIT QTY Code Co-development Program

17

Avalon-MIT QTY Code Co-development Program

QTY code-generated novel therapeutic targets for cancer immunotherapy and other clinical applications

QTYCodeforProteinDesign&Modification

- QTYcodeisageneticmodificationtoolforsystematicallyexchanging(membrane)proteins’primarysequencetoregulateitssolubility

Insolubleó Soluble

*

Designed QTY proteins directly serve as recombinant monoclonal antibodies

Exchanging the sequence origin (host) of the –Fc region can regulate protein’s reactivity

Novel biopharmaceuticals

Novel targets for CAR-T therapy

Design of the QTY receptors resemble structure of common antibodies

QTY Proteins as Decoy Receptors

Bioprocessing / Bioproduction / CDMO

18

Standardized Automation

Process Development

Bio-production

and Training for Cellular Medicines

Bioprocessing / Bioproduction / CDMO

19

20

Core Technology Platform 2:

Stem Cell Exosome Technology

Exosomal biomarkers as disease-associated

Clinical-grade, stem cell-derived exosomes as

“Liquid Biopsy” Diagnostics

Regenerative Therapeutics

J. Rothman T. SudhofR. Schekman

Accreditation/Standardization Infrastructures

June 10, 2019

Source: PR Newswire

ACTEXTM-based ProductsStrategic Partnership

Personal Care / Topical• Wound Management Product• Cosmeceuticals/Skincare• Anti-Scar• Anti-Wrinkle• Diabetic Foot Ulcer• Decubitus Ulcer• Hair Growth

IV / Injectables• Anti-Fibrosis (Liver, Lung)• Neurodegenerative DIsorders

Standardization Strategic Partnership

• Weill Cornell Medicine• New York-Presbyterian Hospital• cGMP Cell Engineering Facility• PI: Yen-Michael Hsu, M.D., Ph.D.

Clinical-Grade, Stem Cell-Derived Exosomes from:

• Mesenchymal Stem Cell (MSC)• Endothelial Progenitor Cell (EPC)• Hematopoietic Stem Cell (HPSC)• Endothelial Cell (EC, HUVEC)• Neural Stem Cell (NSC)• Other Cell Types

Clinical-GradeStem/Progenitor Cells

Bio-production

ACTEXTM

(Avalon Clinical-Grade Tissue-Specific Exosomes)

Avalon’s Clinical-Grade ACTEXTM

21

Avalon GloboCare, part of 25 elite members of ASTCT’s Corporate Council, dedicated to accelerate global development of cellular medicines

Source: www.asbmt.org

Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT)

22

Nasdaq: AVCO

(NASDAQ: AVCO)

Contact:

David Jin, M.D., Ph.D.President & CEOdavid@avalon-globocare.com

Luisa IngargiolaCFOluisa@avalon-globocare.com